You are here

  • Home
  • Archive
  • Volume 70, Issue Suppl 2
  • IDDF2021-ABS-0023 Effectivity of moist exposed burn ointment (MEBO) and the role on reducing the chemotherapy interruption of capecitabine associated hand foot syndrome on stage iii colorectal adenocarcinoma

Article Text

Article menu

Download PDFPDF

Clinical Gastroenterology
IDDF2021-ABS-0023 Effectivity of moist exposed burn ointment (MEBO) and the role on reducing the chemotherapy interruption of capecitabine associated hand foot syndrome on stage iii colorectal adenocarcinoma
Free
  1. Budhi Ida Bagus1,
  2. Agustriani Nunik2,
  3. Ermawan Rieva3,
  4. Suwardi Suwardi2,
  5. Sungkar Amru4,
  6. Saadhi Ikhdin R5,
  7. Mastini Ida Ayu Kade6,
  8. Metria Ida Bagus1,
  9. Setyawati Ida Ayu7
  1. 1Department of Surgery, Sebelas Maret University, Indonesia
  2. 2Pediatric Surgery Department, Sebelas Maret University, Indonesia
  3. 3Orthopaedic Surgery Department, Sebelas Maret University, Indonesia
  4. 4Plastic Surgery Department, Sebelas Maret University, Indonesia
  5. 5Department of Surgery, Moewardi General Hospital, Indonesia
  6. 6Clinical Pharmacy Department, Moewardi General Hospital, Indonesia
  7. 7Medical Faculty, Pendidikan Ganesha University, Indonesia

Abstract

Background A common adverse effect of the fluoropyrimidine chemotherapy agent capecitabine is Hand-foot syndrome (HFS), known as a palmoplantar erythrodysesthesia. Hand-foot syndrome of any grade is reported to affect 43% to 71% of patients treated with single-agent capecitabine chemotherapy. Although HFS is not a life-threatening adverse effect, it can have a great impact on the quality of life (QoL) and daily living activities of a patient. The dose interruptions and reductions are sometimes required after observation of HFS and could impact on dose intensity and clinical outcomes. As an option for the treatment of this case, we would report our single centre study in evaluating the effectiveness of MEBO for stage II and III HFS.

Methods We will evaluate the clinical sign and symptoms of hand-foot syndrome grade II and III associated with capecitabine as an adjuvant chemotherapy agent on advanced-stage colorectal cancer. All patients with HFS will be treated with topical MEBO twice daily, the clinical improvement of the symptoms will be recorded.

Results Eight cases of grade II and III hand-foot syndrome were reported during this study period, 2 patients were grade III HFS (IDDF2021-ABS-0023 Figure 1. Hand foot syndrome pre-treatment) and the others were grade II. The HFS symptoms occurred during the first 3 months after capecitabine administration. These local topical MEBO were administrated twice daily for 3 months following the chemotherapy schedule, pain reduction was achieved with no capecitabine dose interruption and reduction during the chemotherapy period. The allergic reaction was not found during and after MEBO application in this case (IDDF2021-ABS-0023 Figure 2. Hand foot syndrome post-treatment).

Abstract IDDF2021-ABS-0023 Figure 1
Abstract IDDF2021-ABS-0023 Figure 1
Abstract IDDF2021-ABS-0023 Figure 2
Abstract IDDF2021-ABS-0023 Figure 2

Conclusions Since there was no gold standard therapy, moist exposed burn ointment was an effective treatment option in managing HFS, with a good clinical response on reducing the pain without interrupting the capecitabine doses. Early recognition and multimodality treatment is the best effort in treating HFS.

  • moist exposed burn ointment
  • hand-foot syndrome
  • colonic adenocarcinoma

https://doi.org/10.1136/gutjnl-2021-IDDF.110

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.